Friday, December 19, 2008
GSK starting huge study on new type of heart drug
Drugmaker "GlaxoSmithKline PLC is making a big investment in a new type of drug for the gigantic heart disease market, announcing Thursday it is starting a 15,000-patient, late-stage study of its experimental compound darapladib. The drug is meant to keep plaque deposits in heart arteries stable, so they don't rupture - the top cause of heart attacks and strokes. If approved, this would be the first drug in a new class that inhibits an enzyme called Lp-PLA2, Patrick Vallance, head of drug discovery at the British pharmaceutical company, told The Associated Press"